Heart Disease News and Research

Latest Heart Disease News and Research

Nurses use up-to-date techniques to help smokers quit, says RNAO

As World No Tobacco Day 2010 (May 31) approaches, Canadians thinking about quitting smoking can rely on nurses to help them butt out. The Registered Nurses' Association of Ontario says nurses are using the most up-to-date techniques to help smokers quit, which is reducing the number of smokers and preventing diseases.

26 May 2010

Abbott reports positive 6-month results from bioresorbable vascular scaffold trial at EuroPCR 2010

Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).

26 May 2010

Free emergency care training to address sudden cardiac arrest

The National Safety Council today announced it will offer free emergency care training during National CPR & AED Awareness Week (June 1-7). First Aid and CPR with AED is a three-hour online course that teaches participants how to respond should someone need assistance. First aid topics include breathing emergencies, sudden illness and injury, and bleeding.

26 May 2010

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

The highly anticipated first results of the RESOLUTE All Comers study were presented today during the late-breaking clinical trial session of the 2010 EuroPCR meeting. In this novel 2,292-patient randomized trial, the Resolute zotarolimus-eluting stent from Medtronic, Inc. was found to be as safe and effective as the Xience® V everolimus-eluting stent from Abbott Laboratories.

26 May 2010

InspireMD announces next generation MGuard Prime net protective Cobalt Chromium stent system

InspireMD, Ltd. announced today the next generation MGuard stent, MGuard Prime(R), a net protective Cobalt Chromium stent system. MGuard Prime(R) offers an advanced patented Cobalt Chromium design, superior flexibility and excellent deliverability on top of the established benefits of the MGuard MicroNet(R) technology.

26 May 2010

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.

26 May 2010

SunTech Medical's clinical-grade blood pressure technology selected for new Portable PFS

SunTech Medical, a leading manufacturer of blood pressure monitors and OEM non-invasive blood pressure modules, is pleased to announce the selection of their clinical-grade blood pressure technology for the new Portable Pulmonary Function System by Damec.

26 May 2010

Consequences of secrecy in medicine

No one knows how many mothers' and babies' lives have been saved by the obstetrical forceps. This device has been part of the standard equipment of every maternity room for about 250 years. However, a shadow lies over the success story: after the Chamberlen brothers developed the device at the beginning of the 17th century, the brothers and their descendants used it for 3 generations, but kept it a secret from other obstetricians.

26 May 2010

PIONEER trial evaluates new safe concept of stent-drug combination

Blue Medical today announced a major step forward in its quest to improve the quality of life of patients with cardiovascular disease, with the start of the PIONEER trial, in which a new safe concept of stent-drug combination is evaluated.

26 May 2010

Boston Scientific initiates study to compare PROMUS Element Stent to XIENCE PRIME Stent System

Boston Scientific Corporation today announced the initiation of the PLATINUM PLUS clinical trial, an investigator-sponsored research (ISR) study designed to compare the performance of the PROMUS® Element™ Everolimus-Eluting Coronary Stent System to the XIENCE PRIME™ Everolimus-Eluting Coronary Stent System.

26 May 2010

Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 30-36 month follow-up study of patients treated with NX-1207 in Study NX02-0016. The initial study, completed in the U.S. in 2007, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days and 6 months post-treatment with NX-1207 2.5 mg.

26 May 2010

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Eastern Idaho Regional Medical Center (EIRMC), a full-service regional medical center in Idaho Falls, and West Valley Medical Center, a community hospital in Caldwell, will continue to provide in-network medical care to all Medicare Advantage members enrolled in plans offered by Humana, under terms of a renewal agreement announced today.

26 May 2010

Workplace wellness programs improve employer's bottom line

"Who has time?" is a frequent question in response to the suggestion of a medical check-up. Job demands aren't becoming easier to meet in this challenging economy. And there is always a "to-do" list waiting at home. Naturally employees feel these pressures.

26 May 2010

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder in adolescents aged 13 to 17 years.

26 May 2010

Visually-guided laser-balloon catheter stops abnormal electrical pulses in patients with irregular heartbeats

A new treatment known as a visually-guided laser-balloon catheter successfully interrupted abnormal electrical pulses in patients and pigs with intermittent, irregular heartbeats, in a study reported in Circulation: Arrhythmia and Electrophysiology, a journal of the American Heart Association.

26 May 2010

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

At 12 months the NEVO™ Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus® Liberte® according to new data presented today from the NEVO™ RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.

26 May 2010

$FDA warns on possible fracture risk with proton pump inhibitors use$

FDA warns on possible fracture risk with proton pump inhibitors use

The U.S. Food and Drug Administration today warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors. The product labeling will be changed to describe this possible increased risk.

26 May 2010

New approach to prevention and management of Alzheimer's disease

With the aging of nearly 80 million baby boomers, Alzheimer's disease is an impending epidemic that requires a new approach to prevention as well as management of the disease, according to a UC Santa Barbara professor who has co-authored a new book on the topic.

26 May 2010

HDL cholesterol can transform from good to bad actor in heart-disease process

We've all heard about the importance of raising HDL, or the so-called "good" cholesterol, and lowering LDL, or "bad" cholesterol, to improve heart health. While we've come to assume HDL cholesterol is an inherently good thing, a new study shows that for a certain group of patients, this is not always the case. The study is the first to find that a high level of the supposedly good cholesterol places a subgroup of patients at high risk for recurrent coronary events, such as chest pain, heart attack, and death.

26 May 2010

Lumizyme receives FDA approval for patients with late-onset Pompe disease

The U.S. Food and Drug Administration approved Lumizyme (alglucosidase alfa) for patients ages 8 years and older with late-onset (non-infantile) Pompe disease, a rare genetic disorder.

26 May 2010

Heart Disease News and Research

Latest Heart Disease News and Research

Nurses use up-to-date techniques to help smokers quit, says RNAO

Abbott reports positive 6-month results from bioresorbable vascular scaffold trial at EuroPCR 2010

Free emergency care training to address sudden cardiac arrest

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

InspireMD announces next generation MGuard Prime net protective Cobalt Chromium stent system

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

SunTech Medical's clinical-grade blood pressure technology selected for new Portable PFS

Consequences of secrecy in medicine

PIONEER trial evaluates new safe concept of stent-drug combination

Boston Scientific initiates study to compare PROMUS Element Stent to XIENCE PRIME Stent System

Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Workplace wellness programs improve employer's bottom line

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Visually-guided laser-balloon catheter stops abnormal electrical pulses in patients with irregular heartbeats

NEVO Sirolimus-eluting Coronary Stent demonstrates safety and efficacy outcomes at 12 months

FDA warns on possible fracture risk with proton pump inhibitors use

New approach to prevention and management of Alzheimer's disease

HDL cholesterol can transform from good to bad actor in heart-disease process

Lumizyme receives FDA approval for patients with late-onset Pompe disease

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Heart Disease News and Research

Latest Heart Disease News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in